Drugs / TOL-463
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03930745 | Sep 2019 → Dec 2021 | bacterial vaginosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02866227 | Jul 2016 → Jun 2017 | bacterial vaginosis, vulvovaginal candidiasis | Toltec Pharmaceuticals, LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01812889 Comparator | Apr 2013 → Jan 2014 | infective vaginitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOL-463 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01812889 ↗ |
| Modality | Other / unclassified | “a novel boric acid-based vaginal anti-infective with enhanced antibiofilm activity” PMID 30184181 ↗ Feb 2019 |
| Route | Other | “TOL-463 gel and ovule intravaginally” NCT01812889 ↗ |